awmsg logo



fosaprepitant (IVEMEND®)


Reference No. 3789


Appraisal information

fosaprepitant (IVEMEND®) 150 mg powder for solution for infusion


Company: Merck Sharp & Dohme Ltd
BNF category: Gastro-intestinal system
NMG meeting date: 10/10/2018
AWMSG meeting date: 14/11/2018
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download